menu
    • menu
    [{"orgOrder":0,"company":"Onconetix","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Finasteride","moa":"||Steroid 5-alpha-reductase 2","graph1":"Urology","graph2":"Approved FDF","graph3":"Onconetix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconetix \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Onconetix \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Onconetix","sponsor":"Ocuvex Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Termination","leadProduct":"Omidenepag Isopropyl","moa":"Prostanoid EP2 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Onconetix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Onconetix \/ Ocuvex Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Onconetix \/ Ocuvex Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Onconetix

    Menu

    Onconetix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Onconetix

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Onconetix

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omidenepag Isopropyl

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Ocuvex Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

                            Details : Both companies have terminated the merger agreement. Onconetix will continue to advance and remain focused on delivering innovative ophthalmic solutions to the market, such as Omlonti.

                            Product Name : Omlonti

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 26, 2025

                            Lead Product(s) : Omidenepag Isopropyl

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Ocuvex Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Onconetix

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Onconetix

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Finasteride,Tadalafil

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Blue Water Vaccines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announ...

                            Details : The combined company will focus on the R&D and commercialization of proprietary science and technologies for therapeutics, including Entadfi, a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a PDE5...

                            Product Name : Entadfi

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 18, 2023

                            Lead Product(s) : Finasteride,Tadalafil

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Blue Water Vaccines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth